Cyclo Therapeutics Statistics
Total Valuation
CYTH has a market cap or net worth of $20.73 million. The enterprise value is $31.99 million.
| Market Cap | 20.73M |
| Enterprise Value | 31.99M |
Important Dates
The last earnings date was Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTH has 28.77 million shares outstanding. The number of shares has increased by 109.38% in one year.
| Current Share Class | 28.77M |
| Shares Outstanding | 28.77M |
| Shares Change (YoY) | +109.38% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 9.58% |
| Owned by Institutions (%) | 7.88% |
| Float | 11.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.38 |
| Forward PS | 22.02 |
| PB Ratio | -1.54 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17
| Current Ratio | 0.17 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -284.27% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 183.25% |
| Revenue Per Employee | $108,841 |
| Profits Per Employee | -$3.10M |
| Employee Count | 8 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.61% in the last 52 weeks. The beta is -0.57, so CYTH's price volatility has been lower than the market average.
| Beta (5Y) | -0.57 |
| 52-Week Price Change | -49.61% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 47.90 |
| Average Volume (20 Days) | 60,839 |
Short Selling Information
The latest short interest is 736,308, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 736,308 |
| Short Previous Month | 130,996 |
| Short % of Shares Out | 2.56% |
| Short % of Float | 6.40% |
| Short Ratio (days to cover) | 5.58 |
Income Statement
In the last 12 months, CYTH had revenue of $870,725 and -$24.80 million in losses. Loss per share was -$0.92.
| Revenue | 870,725 |
| Gross Profit | 794,477 |
| Operating Income | -24.68M |
| Pretax Income | -19.39M |
| Net Income | -24.80M |
| EBITDA | -24.67M |
| EBIT | -24.68M |
| Loss Per Share | -$0.92 |
Balance Sheet
The company has $928,010 in cash and $12.21 million in debt, giving a net cash position of -$11.28 million or -$0.39 per share.
| Cash & Cash Equivalents | 928,010 |
| Total Debt | 12.21M |
| Net Cash | -11.28M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | -13.47M |
| Book Value Per Share | -0.47 |
| Working Capital | -15.46M |
Cash Flow
In the last 12 months, operating cash flow was -$22.52 million and capital expenditures -$2,420, giving a free cash flow of -$22.52 million.
| Operating Cash Flow | -22.52M |
| Capital Expenditures | -2,420 |
| Free Cash Flow | -22.52M |
| FCF Per Share | -$0.78 |
Margins
| Gross Margin | 91.24% |
| Operating Margin | -2,834.06% |
| Pretax Margin | -2,848.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -109.38% |
| Shareholder Yield | -109.38% |
| Earnings Yield | -119.73% |
| FCF Yield | -108.72% |
Analyst Forecast
The average price target for CYTH is $0.95, which is 31.84% higher than the current price. The consensus rating is "Buy".
| Price Target | $0.95 |
| Price Target Difference | 31.84% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
CYTH has an Altman Z-Score of -45.19 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -45.19 |
| Piotroski F-Score | 3 |